Treatment of recurrent vulvovaginal candidiasis in women planning a pregnancy

Abstract

Treatment of recurrent vulvovaginal candidiasis in women planning a pregnancy Borovikov I.O., Kutsenko I.I., Gerasimenko E.E. Kuban State Medical University, Krasnodar Aim: evaluation of treatment methods for recurrent vulvovaginal candidiasis (VVC) in patients planning pregnancy. Patients and Methods: a comparative, open, randomized study of the results of treatment of 150 women with recurrent vulvovaginal candidiasis (RVVK) in which, after completing the course of the proposed therapy, fertilization took place within  6 months, followed by successful fetal bearing and childbirth: group I (n = 50) - intravaginal clotrimazole cream 2% application once a day for 6 days; II group (n = 50) - polyenic macrolide natamycin intravaginally at a dose of 100 mg once a day for  10 days; III group (n = 50) - orally fluconazole to reduce the recurrence rate of VVC 150 mg every 3 days (1st, 4th and 7th day). The direct microscopy method, measurement of the pH level of the vaginal environment and culture technique was used. Results: it has been established that the intravaginal application of clotrimazole and fluconazole according to the clinical and microbiological efficacy of RVVK therapy is comparable and is 1.6 ± 0.2 times higher in clinical and 1.2 ± 0.15 times in microbiological efficacy than the intravaginal application of natamycin. The advantage of clotrimazole is a faster relief of candidiasis symptoms, a higher safety profile and microbiological sanation from the concomitant opportunistic pathogenic microflora. Key words: recurrent vulvovaginal candidiasis, antimycotics, clotrimazole, natamycin, fluconazole, planning pregnancy. For citation: Borovikov I.O., Kutsenko I.I., Gerasimenko E.E. Treatment of recurrent vulvovaginal candidiasis in women planning a pregnancy // RMJ. 2018. № 2(I). P. 13–18.